IGF1 and glioma: Also, the CSF-R1 inhibitor BLZ945, in glioma-bearing mice, demonstrated reduced expression of M2-like markers in GAMs, which – after the administration of the insulin-like growth factor 1 (IGF-1) and phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) antagonist – reduced the tumor progression, and an increase in the survival time of mice was observed (Coniglio et al., 2012).